Lenalidomide in low and int-1 risk MDS with del5q: efficacy and quality of life

被引：0
|
作者：
Oliva, E. [1 ]
Latagliata, R. [2 ]
Breccia, M. [2 ]
Morabito, F. [3 ]
Ghio, R. [4 ]
Poloni, A. [5 ]
Barate, C. [6 ]
Cortelezzi, A. [7 ]
Ricco, A. [8 ]
Alati, C. [1 ]
Spiriti, M. Aloe [9 ]
Nobile, F. [1 ]
机构：
[1] Azienda Osped BMM, Hematol Unit, Reggio Di Calabria, Italy
[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
[3] Azienda Osped Cosenza, Hematol Unit, Cosenza, Italy
[4] Osped San Martino Genova, Genoa, Italy
[5] Osped Torrette Ancona, Ancona, Italy
[6] Univ Pisa, Dept Oncol Transplant & New Technol Med, I-56100 Pisa, Italy
[7] Osped Maggiore, Milan, Italy
[8] Univ Bari, I-70121 Bari, Italy
[9] Azienda Osped St Andrea, Rome, Italy
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70191-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S123 / S123
页数：1
相关论文
共 50 条
  • [21] Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide
    Germing, U.
    Giagounidis, A.
    Buesche, G.
    Platzbecker, U.
    Goetze, K.
    Nolte, F.
    Schlenk, R. F.
    Letsch, A.
    Ganser, A.
    Luebbert, M.
    Bug, G.
    Schafhausen, P.
    Schemenau, J.
    Haase, D.
    LEUKEMIA RESEARCH, 2013, 37 : S163 - S163
  • [22] Lenalidomide (LEN) in INT 2 and high risk MDS with DEL 5q. Interim results of a phase II trial by the GFM
    Prebet, Burcheri T.
    Beyne-Rauzy, O.
    Mbida, R. M.
    Hoarau, N.
    Legros, L.
    Ravoet, C.
    Dreyfus, F.
    Stamatoullas, A.
    Chaury, M. P.
    Delaunay, J.
    Laurent, G.
    Vey, N.
    Ade, L.
    Gardin, C.
    Fenaux, Pierre
    BLOOD, 2007, 110 (11) : 251A - 252A
  • [23] Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide
    Follo, M. Y.
    Mongiorgi, S.
    Clissa, C.
    Stoyanova, M.
    Paolini, S.
    Quaranta, M.
    Martinelli, G.
    Manzoli, L.
    Cocco, C.
    Finelli, C.
    LEUKEMIA RESEARCH, 2013, 37 : S28 - S28
  • [24] Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)
    Follo, Matilde Y.
    Finelli, Carlo
    Clissa, Cristina
    Mongiorgi, Sara
    Baldazzi, Carmen
    Stanzani, Marta
    Baccarani, Michele
    Cocco, Lucia
    BLOOD, 2013, 122 (21)
  • [25] Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.
    Fenaux, P.
    Glagounidis, A.
    Selleslag, D. L.
    Beyne-Rauzy, O.
    Mittelman, M.
    Muus, P.
    Knight, R. D.
    Fu, T.
    Hellstrom-Lindberg, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q
    Fenaux, Pierre
    Guerci-Bresler, Agnes
    Muus, Petra
    Sekeres, Mikkael A.
    Giagounidis, Aristoteles
    Deeg, H. Joachim
    Greenberg, Peter
    Skikne, Barry
    Yu, Xujie
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] A Proposed Steroid Mobilization Test to Separate Margination From Marrow Suppression and to Determine Drug Cessation for Safety in Lenalidomide-Induced Neutropenia in Non-Del(5q) MDS Low and INT-1 Patients
    Pancari, Philip A.
    Besa, Emmanuel C.
    Quan, Jackie
    Padula, Amanda
    Tubb, Erev E.
    Vvacqua, Raymond
    BLOOD, 2012, 120 (21)
  • [28] Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients
    Briski, Robert E.
    Chien, Kelly S.
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Sasaki, Koji
    Hammond, Danielle
    Short, Nicholas
    Ravandi, Farhad
    Alvarado, Yesid
    Pierce, Sherry A.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 4042 - 4044
  • [29] Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide
    Giagounidis, Aristoteles A.
    Haase, Sabine
    Platzbecker, Uwe
    Germing, Ulrich
    Lohrbacher, Vera
    Ehninger, Gerhard
    Aul, Carlo
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [30] IMPACT OF MDS ON HEALTH-RELATED QUALITY OF LIFE: A COMPARISON OF IPSS LOW-AND INT-1 RISK MDS PATIENTS FROM THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY AND EUROPEAN REFERENCE POPULATIONS
    Stauder, R.
    Bagguley, T.
    Smith, A.
    Fenaux, P.
    Symeonidis, A.
    Cermak, J.
    Sanz, G.
    Hellstrom-Lindberg, E.
    Mittelman, M.
    Malcovati, L.
    Huls, G.
    Madry, K.
    Germing, U.
    Tatic, A.
    Holm, M. S.
    Savic, A.
    Droste, J.
    Guerci-Bresler, A.
    Slama, B.
    Luno, E.
    Culligan, D.
    de Swart, L.
    Johnston, W. T.
    Bowen, D.
    de Witte, T.
    HAEMATOLOGICA, 2015, 100 : 68 - 69
12345